OpenFilings

PharmaCyte Biotech, Inc.

Form10-K

Report Period2022-04-30

Date Filed2022-07-28

Time Filed17:29:10

Document Analysis

Natural Language Processing

Recognized Type Unidentified

Defined Term Format

Exhibits

FORM 10-K
DESCRIPTION OF SECURITIES
AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT, DATED MAY 8, 2022, BETWEE
AMENDED AND RESTATED EXECUTIVE COMPENSATION AGREEMENT, DATED MAY 8, 2022, BETWEE
PHARMACYTE BIOTECH, INC. 2021 EQUITY INCENTIVE PLAN.
LIST OF SUBSIDIARIES
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
CERTIFICATION
CERTIFICATION
CERTIFICATION
CERTIFICATION
Filing on SEC Edgar